ZIKALIVAX 2.0 (Q3712907)

From EU Knowledge Graph
Revision as of 07:03, 2 December 2021 by DG Regio (talk | contribs) (‎Created claim: summary (P836): Die Arbeit des Postdoktorats zielt darauf ab, den abgeschwächten Virusstamm ZIKALIVax experimentell als Kandidaten für Lebendimpfstoffe gegen ZIKA-Fieber zu validieren., translated_summary)
Jump to navigation Jump to search
Project Q3712907 in France
Language Label Description Also known as
English
ZIKALIVAX 2.0
Project Q3712907 in France

    Statements

    country
    France
    0 references
    EU contribution
    63,811.94 Euro
    0 references
    budget
    99,706.15 Euro
    0 references
    co-financing rate
    64.0 percent
    0 references
    start time
    1 September 2017
    0 references
    end time
    31 August 2019
    0 references
    beneficiary name (string)
    UNIVERSITÉ DE LA RÉUNION
    0 references
    beneficiary
    Q3775809
    0 references
    summary
    Les travaux menés par le post-doctorant visent à valider expérimentalement la souche virale atténuée ZIKALIVax comme un candidat vaccin vivant contre la fièvre ZIKA. (French)
    0 references
    The postdoctoral research aims at experimentally validating the attenuated viral strain ZIKALIVax as a live vaccine candidate against ZIKA fever. (English)
    point in time
    22 November 2021
    0 references
    Die Arbeit des Postdoktorats zielt darauf ab, den abgeschwächten Virusstamm ZIKALIVax experimentell als Kandidaten für Lebendimpfstoffe gegen ZIKA-Fieber zu validieren. (German)
    point in time
    2 December 2021
    0 references

    Identifiers

    French Kohesio ID
    RE0012406
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q3712907&oldid=17138585"